A novel CLTC‐FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone

2020 ◽  
Vol 60 (1) ◽  
pp. 38-42
Author(s):  
Julia A. Bridge ◽  
Janos Sumegi ◽  
Thomas Royce ◽  
Michael Baker ◽  
Konstantinos Linos
Keyword(s):  
Gene Fusion ◽  
Pseudomyogenic Hemangioendothelioma ◽  
Hemangioendothelioma Of Bone

scholarly journals Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Weijie Chen ◽  
Huimei Wang ◽  
Dongxian Jiang ◽  
Lijuan Luan ◽  
Yuhong Zhou ◽  
...  
Keyword(s):  
Gene Fusion ◽  
Immunohistochemical Analysis ◽  
Genetic Alterations ◽  
Detection Methods ◽  
Gene Fusions ◽  
Term Survival ◽  
Pseudomyogenic Hemangioendothelioma ◽  
Dendritic Cell Sarcoma ◽  
Trk Inhibitors

Abstract Background Mesenchymal sarcomas are tumors that originate from mesenchymal tissue. Most mesenchymal sarcomas can be accurately classified, but some are unclassifiable in clinical practice. Molecular detection methods enable patients to benefit from molecular-targeted therapies for many cancers, including lung, breast, and bowel cancers. Further, even unclassified tumors can have therapeutic targets. NTRK gene fusions are sporadic genetic alterations that occur across tumor entities. If NTRK gene fusions are detected, TRK inhibitors can be used regardless of the tumor entity. Case presentation This report describes a case with an unclassifiable mesenchymal sarcoma carrying a neurotrophic tyrosine receptor kinase NTRK1-KHDRBS1 gene fusion that was diagnosed and treated at multiple hospitals. Diagnostic work-up included pathological and immunohistochemical analysis, which excluded angiosarcoma, dendritic cell sarcoma, and pseudomyogenic hemangioendothelioma. The patient achieved a long-term survival without tumor relapse after treatment with crizotinib. Conclusions This case will be of significant interest to pathologists because, despite the tumor being unclassified, a molecular target was identified. Although the FDA does not currently approve crizotinib for treatment of patients harboring NTRK gene fusions, this case provides new insights for diagnosis and treatment of mesenchymal sarcomas with NTRK1 gene translocations. Similar to ALKomas, which can be successfully treated using NTRK molecular-targeted therapy, tumors with NTRK gene translocations can be classified as NTRKomas, even when they occur at different organ sites, and with varying histological morphologies, and immunophenotypes.

The cytologic features of primary pseudomyogenic hemangioendothelioma of bone

2021 ◽  
Author(s):  
Bryce S. Hatfield ◽  
Steven C. Smith ◽  
Sosipatros A. Boikos ◽  
Sadia Sayeed
Keyword(s):  
Pseudomyogenic Hemangioendothelioma ◽  
Hemangioendothelioma Of Bone

scholarly journals Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Shinya Otani ◽  
Robert Nakayama ◽  
Tetsuya Sekita ◽  
Toru Hirozane ◽  
Naofumi Asano ◽  
...  
Keyword(s):  
Case Report ◽  
Pseudomyogenic Hemangioendothelioma ◽  
Hemangioendothelioma Of Bone

Primary Pseudomyogenic Hemangioendothelioma of Bone

2016 ◽  
Vol 40 (5) ◽  
pp. 587-598 ◽  
Author(s):  
Alero Inyang ◽  
Fredrik Mertens ◽  
Florian Puls ◽  
Vaiyapuri Sumathi ◽  
Carrie Inwards ◽  
...  
Keyword(s):  
Pseudomyogenic Hemangioendothelioma ◽  
Hemangioendothelioma Of Bone

scholarly journals Pseudomyogenic hemangioendothelioma of bone with rare WWTR1‐FOSB fusion gene: Case report and literature review

2021 ◽  
Author(s):  
Khaled A. Murshed ◽  
Jorge Torres‐Mora ◽  
Ahmed Mounir ElSayed ◽  
Adham Ammar ◽  
Issam Al‐Bozom
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Fusion Gene ◽  
Pseudomyogenic Hemangioendothelioma ◽  
Hemangioendothelioma Of Bone
Sign in / Sign up

Export Citation Format

Share Document